FDA Inspection 1217732 — Guilin Pharmaceutical Co., Ltd.
The FDA completed an inspection of Guilin Pharmaceutical Co., Ltd. on August 18, 2023 in Guilin. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 18, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Guilin (China)